Stanley Gallagher, DO
Family Medicine · Sisseton, SDNPI 1831125657
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.
Across 106 payments — averaging $13.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$295
- Pfizer$121
- Lilly USA, LLC$118
- Phathom Pharmaceuticals, Inc.$110
- Boehringer Ingelheim$94
- Novo Nordisk$72
- plus $627 from 20 others
What the payments were for
- Food & beverage$1,42599%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 28 | $295 |
| Pfizer | 8 | $121 |
| Lilly USA, LLC | 8 | $118 |
| Phathom Pharmaceuticals, Inc. | 8 | $110 |
| Boehringer Ingelheim | 7 | $94 |
| Novo Nordisk | 5 | $72 |
| Novartis | 4 | $70 |
| Merck | 5 | $67 |
| AbbVie | 3 | $47 |
| AstraZeneca(2 entities) | 4 | $46 |
| Exact Sciences | 3 | $46 |
| Mylan Specialty L.p. | 3 | $41 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Biogen | 2 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Electromed, Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Pelvital USA, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Organon | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$1,436 in reported general payments places this provider in the 85th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArexvyRsvpref3 Antigen/As01e/Pf | 460 | $133,684 |
| EliquisApixaban | 164 | $115,922 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 502 | $103,212 |
| JardianceEmpagliflozin | 142 | $83,634 |
| XareltoRivaroxaban | 133 | $75,649 |
| OzempicSemaglutide | 66 | $71,465 |
| JanuviaSitagliptin Phosphate | 67 | $61,394 |
| MresviaRsv Vaccine, Pref, Mrna/Pf | 124 | $37,867 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 44 | $32,514 |
| TrulicityDulaglutide | 28 | $29,240 |
| MyrbetriqMirabegron | 80 | $22,269 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 145 | $19,094 |
| InvokanaCanagliflozin | 13 | $18,840 |
| VraylarCariprazine Hcl | 26 | $18,636 |
| XifaxanRifaximin | 12 | $18,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $121 | $121,064181 claims |
| Johnson & JohnsonXarelto, Invokana | $295 | $94,489146 claims |
| MerckJanuvia, Janumet Xr | $67 | $93,908111 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $94 | $93,774162 claims |
| Novo NordiskOzempic | $72 | $71,46566 claims |
| Lilly USA, LLCTrulicity | $118 | $29,24028 claims |
| AbbVieVraylar, Lumigan | $47 | $24,22237 claims |
| AstraZenecaFarxiga | $46 | $17,33134 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $40 | $16,65419 claims |
| NovartisEntresto | $70 | $9,25411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Sisseton
- Kyla Helm-SwansonRapid City$22K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
- Scott BoyensSioux Falls$6K
- Terry GraberCuster$6K
- Christi ChildersSpearfish$6K
- Jonathan McAreaveyWatertown$5K
- Kinsey Shultz PiatzRapid City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.